References
- Cardoso F, Costa A, Senkus E, et al. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). The Breast. 2017;31:244–259.
- Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914–923.
- Rasmussen ML, Liposits G, Yogendram S, et al. Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer. Acta Oncol. 2014;53:1275–1277.
- Unger JM, Barlow WE, Martin DP, et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst. 2014;106:dju002.
- Kessler L, Falato C, Margolin S, et al. A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden. Acta Oncol. 2015;54:522–529.
- Tesch H, Schneeweiss A. Practical experiences with eribulin in patients with metastatic breast cancer. Anticancer Drugs. 2016;27:112–117.
- Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. JCO 2015;33:594–601.
- Pivot X, Marmé F, Koenigsberg R, et al. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016;27:1525–1531.
- Twelves C, Awada A, Cortes J, et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer (Auckl). 2016;10:77–84.